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Heart failure (HF) is framed in one of the types of cardiovascular diseases; it 
consists of an acute and chronic form. The disease can evolve slowly from 
asymptomatic left ventricular dysfunction, to a state of severe disability, 
presenting a wide prevalence in the population around 10% in people over 
70 years old. More than three-quarters of the deaths from this pathology 
normally occur in low or middle-income countries. Angola is not exempt from 
this health problem be observed in a relatively young people, bringing 
disability and death at an early stage of life. Scientific advances and 
innovative treatments for the control and prevention of the disease continue 
to be insufficient.
The ozone for it’s antioxidant, hemorehological properties, oxygenation 
enhancers and blood circulation is an alternative treatment for these 
patients.
We have performed a study where 45 patients who were diagnosed with a 
chronic stage of II-III HF due to the functional classification of the New York 
Heart Association (NYHA) and American Cardiology College / American 
Heart Association (ACC / AHA), previous echocardiogram with a Fracture of 
Left Ventricular Ejection (LVEF) less than 45%. We administered a Major 
Autohemotherapy with a protocol of 15 sessions, maintenance every 15 
days and cycles every 6 months at 50 µg of concentration, an initial dose of 
4,000 µg / mL up to 12,000 µg / mL during the 3 years of treatment.
Patients after the first treatment cycle improve their functional physical 
capacity and LVEF increased to normal levels (55%). It was proved that 
Autohemotherapy is an adjuvant, viable and beneficial treatment in chronic 
HF.
Keywords:  Heart failure, major autohemotherapy, ozone therapy, left ventricular ejection 
fraction 
Introduction 
Heart failure (HF) is a worldwide public health problem in developed 
countries, approximately 2% of the adult population has HF, a prevalence 
that increases exponentially with age, as it is less than 1% before the 50 
years and then doubles with each decade to exceed 8% among those over 
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HF is the inability of the heart to pump blood properly according to the needs 
of the hepatic metabolism; if it succeeds, it does so at the expense of an 
abnormal elevation of the filling pressure of the cardiac ventricles either by 
myocardial disease or excessive overload. This brings with it a 
neurohormonal response with effort intolerance, fluid retention and reduced 
longevity.
In 2003, the American Heart Association (AHA) reported that 48 million 
hospital discharges occurred in the United States with this diagnosis [3]. In 
the Framingham study, HF in men aged 50-59 years was 8 per 1,000 
inhabitants and increasing to 70 per 1,000 in patients over 80 years (very 
similar numbers in women) [4].
However, in Africa it has a rather different etiology to that described in 
Europe and America, it is related to the degree of development of the 
continent and affects predominantly a young population. Damasceno, in his 
study on heart failure in Africa, throughout a meta-analysis including studies 
published up to 2007 by Bongani Mayosi et al. [5] found that arterial 
hypertension was the main cause of heart failure followed by 
cardiomyopathies.
The current therapeutic approach of patients with HF is aimed at improving 
signs and symptoms, correcting volume overload, increasing end-organ 
perfusion, improving cardiac contractility and hemodynamic status [6].
During the last 24 years, the mechanisms of action of ozone in human blood 
have been clarified [7]. It is stated that its therapeutic properties are: 
improving the metabolism of oxygen, modulate biological oxidative stress, 
modulate the immune system, intervene in the synthesis and / or release of 
autacoids (endogenous substances with diverse actions physiological and 
pharmacological), regulate metabolism, in addition to exert a great effect as 
germicide [8].
For all of the above, our team decided to analyze the clinical and 
echocardiographic (LVEF) effects induced by major autohemotherapy 
applied in patients with CHF.
Materials and methods 
A retrospective cross-sectional study was performed at the Cardiozono 
Medical Center located in Luanda, Angola. The final sample consisted of 45 
patients of both sexes, who presented a diagnosis of CHF, referred from our 
Cardiology Department and other Hospital offices, who started treatment of 
ozone therapy indistinctly in the period from June 2014 to June 2017. We 
emphasize that in our work we performed an analysis of the patients treated 
in this time period of their evolution corresponding to one year performing 
the therapy.
Inclusion criteria were: 
Patients with a diagnosis of HFC class II-III of the New York Heart 
Association (NYHA) [9] and American Cardiology College / American Heart 
Association (ACC / AHA), previous echocardiography with a (LVEF) between 
35% and 50% and patients with a time greater than 6 months of treatment 
with furosemide 40 mg at 8 hours and 40 mg at 16 hours, spironolactone 50 
mg every 12 hours, hydrochlorothiazide 25 mg daily, carvedilol 12.5 mg 
every 12 hours, mononitrate of isosorbide 20 mg daily and aspirin 100 mg 
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treatment, 20 were women and 25 men, the age of the patients was from 40 
to 65 years, (60 to 65 years, 20 patients, 11 women and 9 men, from 50 to 
59 years, 20 patients, 13 men and 7 women and from 40 to 49 years old, 5 
patients, 3 men and 2 women).
Exclusion criteria were: 
Patients with HF of a diagnosis (less than 6 months) with medical treatment 
and patients with secondary HF produced by autoimmune diseases. 
Treatment Protocol: 
The patients received 15 sessions of major autohemotherapy (one daily 
session). In each session we used a German-made Promedic Humazon 
equipment (Humares GmbH, Bruchsal, Germany), 3-way stopcock, 
epicranial needle 19 G, Sangiset (Humares GmbH, Bruchsal, Germany) with 
capacity of 350 mL where we put 10 mL of 3.13 % sodium citrate to avoid 
blood clot during the procedure and other disposable material.
The major autohemotherapy (Table 1) was performed at a concentration of 
50 μg / mL in 100 m of blood; the initial dose of the therapy was 4000 μg (80 
mL of ozone gas at 50 μg / mL concentration); we increased the dose by 
2000 μg every 2 days until reaching a dose of 12000 μg (240 mL of ozone 
gas at 50 μg / mL concentration), maintaining this dose as a maintenance 
dose every 15 days throughout the year. 
The parameters evaluated were:
• Heart failure Functional Classification according NYHA [9] (New York Heart 
Association) (Table 2)
• Ejection Fraction Classification according NYHA [9]:
- Ejection fraction NORMAL ≈ 50-70% is expelled during each contraction 
(there is usually a sense of comfort during physical activities)
- Ejection fraction LIMIT ≈ 41-49% is expelled during each contraction 
(symptoms may be more noticeable during physical activity)
- Reduced ejection fraction ≤ 40% is expelled during each contraction 
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Table 1: Ozone Treatment protocol
Days of treatment Amount of O3 (µg)
Days 1-2 (4000) µg per 100 mL, 50 µg/mL
Days 3-4 (6000) µg per 100 mL, 50 µg/mL
Days 5-6 (8000) µg per 100 mL, 50 µg/mL
Days 7-8 (10000) µg per 100 mL, 50 µg/mL
Days 9-15 (12000) µg per 100 mL, 50 µg/mL
Maintenance every 15 days (12000) µg per 100 mL, 50 µg/mL
JO3TJavier Cespedes-Suarez
Statistical analysis: 
We used SPSS 19.0 statistic software and we categorized the values using 
contingency tables utility and chi-square analysis for the significance on the 
changes before and after the treatment. Values of chi-square under 0,05 
were considered significant. 
Results and Discussion 
The NYHA functional classification assesses the physical activity of the 
patient with CHF, based on the subjective assessment made by the 
physician during the examination of the presence and severity of dyspnoea. 
This has an important prognostic value since it allows following the evolution 
and response to the treatment [9].
During ozone therapy, we observed that most of the patients were in class III 
for 66.7% of the patients before starting the treatment. At 45 days after the 
15 sessions, a significant change was observed, with 86.7% cases in class 
II, results that remained in progress throughout the year under treatment 
until reaching 53.3% of them to class I. (Table 3).
This process suggests that the response of the organism to 
autohemotherapy with the doses used was favorable, although it is not able 
to eradicate the disease; it tends to significantly improve the functional 
limitations of HF, which agrees with similar studies [10].
The ejection fraction was assessed during different stages of our study 
(Table 4). Before starting treatment, most patients had an LVEF of 35-40 for 
22.2%, and 44.4% had a Fraction of Erection of 45-50 per year, attributing 
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Tabla 2. Functional Classification of NYHA (New York Heart Association) HF.
CLASS CHARACTERÍSTICS DEFINITIÓN
I
Without limitation: normal physical 
exercise does not cause fatigue, 




Slight limitation of physical activity: 
without symptoms at rest, normal physical 




Charged physical limitation: no symptoms 




Inability to perform physical activity: the 
symptoms of heart failure are present 




improves the metabolism of the cardiac muscle, increases the circulating 
serotonin and causes a cardioprotective effect already mentioned in previous 
studies [11,12].
Conclusions 
This study strongly suggests that the application of major autohemoterapy 
produced a clinical and functional improvement in patients with CHF, 
evidencing its effectiveness as adjuvant therapy.
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Tabla 3. Behavior of the Functional Classification of HF in 45 patients treated with 
ozone therapy.
CLASS Before starting 
treatment
45 days after completion 
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